Organogenesis Holdings Inc.
No SEC Form 4 filings for $ORGO in the last 30 days.
See all $ORGO insider activity →Organogenesis reported that a peer-reviewed study found its PuraPly AM product, combined with standard care, significantly improved 12-week wound closure in diabetic foot ulcers compared to standard care alone, according to the company.
Organogenesis Holdings Inc. (ORGO) will release its Q3 2026 financial results after market close on Nov. 5. A conference call is scheduled for 5 p.m. ET to discuss results and provide a corporate update. The webcast will be available live and archived on the company's website.
Organogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ORGO (Organogenesis Holdings Inc.). Coverage has skewed bullish: 3 bullish, 1 neutral, and 0 bearish.
Recent ORGO coverage spans earnings, financial news and corporate actions.
Positive trial data is likely to lift ORGO as investors anticipate reimbursement and revenue upside.
The announcement provides the timing of the earnings release but contains no new financial data.
Near-term sentiment is pressured by CMS-related market contraction and a more measured 2026 recovery, partially offset by sequential improvement and clinical evidence updates.
The 8-K discloses an ATM equity issuance capacity, which can pressure near-term valuation via dilution risk and signal funding needs.
The filing discloses a sharp revenue contraction and materially worse losses, signaling continued demand and/or reimbursement pressure and higher burn.
AlphAI scores every news story that mentions ORGO with an AI model for sentiment and relevance, and aggregates insider trades from Organogenesis Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Organogenesis reported that a peer-reviewed study found its PuraPly AM product, combined with standard care, significantly improved 12-week wound closure in diabetic foot ulcers compared to standard care alone, according to the company.
1 min readOrganogenesis Holdings Inc. (ORGO) will release its Q3 2026 financial results after market close on Nov. 5. A conference call is scheduled for 5 p.m. ET to discuss results and provide a corporate update. The webcast will be available live and archived on the company's website.
1 min readOrganogenesis (ORGO) reported Q2 2026 revenue down 58% year over year, driven by a 61% drop in Advanced Wound Care sales. Net product revenue rose 18% quarter over quarter. The company cited CMS coverage changes as slowing recovery, announced a June restructuring with 138 job cuts and about $18M annualized cost savings, and updated 2026 revenue guidance. It also cited DFU and venous ulcer study results and FDA acceptance of Amnuvx BLA with a PDUFA date of Apr 24, 2027.
10 min readOrganogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 6, 2026, Organogenesis Holdings Inc. (the “Corporation”) entered into an At-the-Market Sales Agreement (the “Sales Agreement”) with BTIG, LLC (“BTIG”) and Citizens JMP Securities, LLC (“Citizens” and together with BT
4 min readOrganogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results CANTON, Mass., (August 6, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing
6 min readOrganogenesis Holdings Inc. (Nasdaq: ORGO) said it will release second-quarter fiscal 2026 financial results after market close on Aug. 6, 2026. The company will hold a conference call at 5:00 p.m. ET the same day to discuss results and provide a corporate update with Q&A. The webcast will be available on its investor site.
2 min readOrganogenesis Holdings (ORGO) said the FDA accepted its BLA for ReNu, a cryopreserved amniotic suspension allograft for pain in symptomatic knee osteoarthritis. The company cited 3 randomized trials with 1,300+ patients and prior RMAT designation (2021). FDA set a PDUFA action date of April 24, 2027; “Amnuvx” is conditionally accepted as the proprietary name.
3 min readOrganogenesis Holdings (Nasdaq: ORGO) said the FDA accepted for review its Biologics License Application for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis pain. The FDA set a PDUFA target action date of April 24, 2027. The company noted ReNu has RMAT designation and was studied in three RCTs (>1,300 patients).
3 min readOrganogenesis Holdings Inc. (ORGO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K NASDAQ false 0001661181 0001661181 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): Ju
3 min readOrganogenesis Holdings Inc. announced the extension of lease agreements for two facilities in Canton, Massachusetts, through December 31, 2032, with an option for renewal until 2034. These facilities are crucial for the company's manufacturing, operations, and research and development activities. The lease amendments were approved by the Audit Committee, considering that some major stockholders indirectly own the properties.
2 min read
